(Enoblituzumab)Biosimilar Reference Antibody-GS40229 新品

货号：GS40229

Enoblituzumab (development code MGA271) is an investigational, humanized Fc-engineered monoclonal IgG1 antibody developed for the treatment of solid tumors. Its design incorporates a modified Fc domain to enhance immune activation. Enoblituzumab functions as a targeted immunotherapeutic agent by binding to a specific antigen highly expressed on a variety of cancer cells. The antibody's primary anti-tumor mechanism is believed to be antibody-dependent cellular cytotoxicity (ADCC), where its optimized Fc region potently engages natural killer (NK) cells and other immune effector cells to kill the bound tumor cells. It may also inhibit pro-tumorigenic signaling pathways within the cancer cell.